» Articles » PMID: 34526526

Versatile Cell-based Assay for Measuring DNA Alkylation Damage and Its Repair

Overview
Journal Sci Rep
Specialty Science
Date 2021 Sep 16
PMID 34526526
Citations 2
Authors
Affiliations
Soon will be listed here.
Abstract

DNA alkylation damage induced by environmental carcinogens, chemotherapy drugs, or endogenous metabolites plays a central role in mutagenesis, carcinogenesis, and cancer therapy. Base excision repair (BER) is a conserved, front line DNA repair pathway that removes alkylation damage from DNA. The capacity of BER to repair DNA alkylation varies markedly between different cell types and tissues, which correlates with cancer risk and cellular responses to alkylation chemotherapy. The ability to measure cellular rates of alkylation damage repair by the BER pathway is critically important for better understanding of the fundamental processes involved in carcinogenesis, and also to advance development of new therapeutic strategies. Methods for assessing the rates of alkylation damage and repair, especially in human cells, are limited, prone to significant variability due to the unstable nature of some of the alkyl adducts, and often rely on indirect measurements of BER activity. Here, we report a highly reproducible and quantitative, cell-based assay, named alk-BER (alkylation Base Excision Repair) for measuring rates of BER following alkylation DNA damage. The alk-BER assay involves specific detection of methyl DNA adducts (7-methyl guanine and 3-methyl adenine) directly in genomic DNA. The assay has been developed and adapted to measure the activity of BER in fungal model systems and human cell lines. Considering the specificity and conserved nature of BER enzymes, the assay can be adapted to virtually any type of cultured cells. Alk-BER offers a cost efficient and reliable method that can effectively complement existing approaches to advance integrative research on mechanisms of alkylation DNA damage and repair.

Citing Articles

Realistic aspects behind the application of the rat model of chemically-induced mammary cancer: Practical guidelines to obtain the best results.

Silva J, Faustino-Rocha A, Duarte J, Oliveira P Vet World. 2023; 16(6):1222-1230.

PMID: 37577198 PMC: 10421542. DOI: 10.14202/vetworld.2023.1222-1230.


Deficiency in mammalian STN1 promotes colon cancer development via inhibiting DNA repair.

Nguyen D, Kim E, Le N, Ding X, Jaiswal R, Kostlan R Sci Adv. 2023; 9(19):eadd8023.

PMID: 37163605 PMC: 10171824. DOI: 10.1126/sciadv.add8023.

References
1.
Beranek D . Distribution of methyl and ethyl adducts following alkylation with monofunctional alkylating agents. Mutat Res. 1990; 231(1):11-30. DOI: 10.1016/0027-5107(90)90173-2. View

2.
Fu D, Calvo J, Samson L . Balancing repair and tolerance of DNA damage caused by alkylating agents. Nat Rev Cancer. 2012; 12(2):104-20. PMC: 3586545. DOI: 10.1038/nrc3185. View

3.
Margison G, Koref M, Povey A . Mechanisms of carcinogenicity/chemotherapy by O6-methylguanine. Mutagenesis. 2002; 17(6):483-7. DOI: 10.1093/mutage/17.6.483. View

4.
Saffhill R, Margison G, OConnor P . Mechanisms of carcinogenesis induced by alkylating agents. Biochim Biophys Acta. 1985; 823(2):111-45. DOI: 10.1016/0304-419x(85)90009-5. View

5.
Klapacz J, Lingaraju G, Guo H, Shah D, Moar-Shoshani A, Loeb L . Frameshift mutagenesis and microsatellite instability induced by human alkyladenine DNA glycosylase. Mol Cell. 2010; 37(6):843-53. PMC: 2894629. DOI: 10.1016/j.molcel.2010.01.038. View